Online inquiry

IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11257MR)

This product GTTS-WQ11257MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11257MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2681MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ3139MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ1160MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ5383MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ5101MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ7460MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ9381MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ8751MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW